Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

ClinicalTrials.gov ID: NCT04895982

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04895982. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 2b, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162b2 IN IMMUNOCOMPROMISED PARTICIPANTS ≥2 YEARS OF AGE

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised. Participants are going to be followed up for 6 months after dose 4, and each participant is projected to be on the study for approximately 15 months. This study will be conducted in the United States, Brazil, Germany and Mexico.

Study identification

NCT ID
NCT04895982
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
BioNTech SE
Industry
Enrollment
124 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
2 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 15, 2021 (Actual)
Primary completion
Jul 23, 2023 (Actual)
Completion
Jul 23, 2023 (Actual)
Last update posted
Oct 9, 2024

2021 – 2023

United States locations

U.S. sites
15
U.S. states
5
U.S. cities
7
Facility City State ZIP Site status
Ochsner Clinic Foundation Jefferson Louisiana 70121 —
Ochsner Medical Center - Jefferson Highway Jefferson Louisiana 70121 —
Ochsner Clinic Foundation Kenner Louisiana 70065 —
Ochsner Medical Center Kenner Kenner Louisiana 70065 —
Ochsner Clinic Foundation New Orleans Louisiana 70121 —
Ochsner Medical Center - Jefferson Highway New Orleans Louisiana 70121 —
Henry Ford Health System Detroit Michigan 48202 —
Henry Ford Hospital - Research Pharmacy Detroit Michigan 48202 —
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45206 —
Cincinnati Children's Hospital Medical Center Cincinnati Ohio 45229 —
Cincinnati Children's Hospital Vaccine Research Center Cincinnati Ohio 45229 —
Cincinnati Children's Hospital Cincinnati Ohio 45229 —
Texas Children's Hospital Houston Texas 77030 —
Seattle Children's Research Institute: Building Cure Seattle Washington 98101 —
Seattle Children's Hospital Seattle Washington 98105 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04895982, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 9, 2024 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.